problems with glp-1 drugs Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity Comparing Ozempic, Wegovy and Other
Description
New users of GLP-1RAs were matched based on age, demographics, comorbidities and medication use by using 1:1 propensity matching with other glucose-lowering drugs
Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov
Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials
It also encourages feelings of fullness, which can help reduce cravings and support consistent, long-term wellness as part of a balanced lifestyle
Semaglutide was removed in February 2025
